



### Viberzi<sup>®</sup> (eluxadoline) – New warning

- On April 13, 2018, the [FDA approved](#) an update to the *Warnings and Precautions* section of the [Viberzi \(eluxadoline\)](#) drug label regarding constipation.
- Viberzi is approved in adults for the treatment of irritable bowel syndrome with diarrhea.
- Constipation, sometimes requiring hospitalization, has been reported following Viberzi administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported.
  - Patients should be instructed to stop Viberzi and immediately contact their healthcare provider if they experience severe constipation.
  - Viberzi use should be avoided with other drugs that may cause constipation.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.